Abstract
ABSTRACT
This study evaluated the influence of receptor/G-protein (R:G) stoichiometry on constitutive activity and the efficacy of agonists, partial agonists, and inverse agonists at human (h) 5-hydroxytryphamine 1B (5-HT1B) receptors. Two Chinese hamster ovary cell lines were used; they expressed 8.5 versus 0.4 pmol h5-HT1B receptors/mg (determined by [3H]GR125,743 saturation analysis) and 3.0 versus 1.5 pmol receptor-activated G-proteins/mg [determined by guanosine-5′-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) isotopic dilution], respectively. Thus, they displayed R:G ratios of ∼3.0 (RGhigh) and ∼0.3 (RGlow), respectively. In competition-binding experiments, the agonists, 5-HT and sumatriptan, displayed fewer high-affinity (HA)-binding sites and the partial agonists, BMS181,101 and L775,606, displayed decreased affinity in RGhigh versus RGlow membranes. In contrast, the inverse agonists, SB224,289 and, to a lesser extent, methiothepin, showed increased affinity. In G-protein activation experiments, both basal and 5-HT-activated [35S]GTPγS binding were higher in RGhigh than in RGlow membranes. Constitutive activity (determined by inhibition of basal [35S]GTPγS binding with GTPγS in the absence of receptor ligands) was more pronounced in RGhigh versus RGlow membranes, as revealed by the >5-fold greater proportion of HA sites. Correspondingly, the negative efficacy of inverse agonists was strikingly augmented, inasmuch as they suppressed approximately two-thirds of HA [35S]GTPγS binding in RGhigh membranes, but only approximately one-third in RGlow membranes. Furthermore, the efficacy of partial agonists was greater at RGhigh versus RGlow membranes, as estimated by their ability to enhance [35S]GTPγS binding. In conclusion, an increase in R:G ratios at h5-HT1B receptors was associated with an increase in relative efficacy of partial agonists and, most notably, an increase in both constitutive G-protein activation and negative efficacy of inverse agonists.
Footnotes
- Received May 8, 2000.
- Accepted July 25, 2000.
-
Send reprint requests to: Adrian Newman-Tancredi, Ph.D., Department of Psychopharmacology, Institut de Recherches Servier, 125 chemin de Ronde, 78290, Croissy-sur-Seine (Paris), France. E-mail: newman_tancredi{at}hotmail.com
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|